Is Entero Healthcar overvalued or undervalued?

As of 14 November 2025, Entero Healthcare's valuation grade has moved from attractive to very attractive, indicating a stronger positive outlook. The company is currently considered undervalued. Key ratios include a PE ratio of 44.13, an EV to EBITDA of 23.43, and a PEG ratio of 0.31, which suggests significant growth potential relative to its price. In comparison to its peers, Entero Healthcare's PE ratio is notably higher than TCS at 22.34 and Infosys at 22.19, both of which are in a lower valuation category. Additionally, while Entero's EV to EBITDA is higher than the industry average, its PEG ratio indicates that it may be undervalued relative to its growth prospects. Despite recent stock performance trailing the Sensex over the year, Entero Healthcare's strong ratios and improved valuation grade suggest it presents a compelling investment opportunity.